Relationship between Drug Release of DE-310, Macromolecular Prodrug of DX-8951f, and Cathepsins Activity in Several Tumors
Open Access
- 1 January 2007
- journal article
- Published by Pharmaceutical Society of Japan in Biological & Pharmaceutical Bulletin
- Vol. 30 (12), 2365-2370
- https://doi.org/10.1248/bpb.30.2365
Abstract
DE-310 is composed of the topoisomerase-I inhibitor DX-8951 (exatecan) and carboxymethyldextran polyalcohol (CM-Dex-PA) carrier, which are covalently linked via peptidyl spacer (Gly-Gly-Phe-Gly). In this study, we investigated relationship between the cathepsin activity and the drug release of DE-310 by use of human liver origin cathepsin (B, L and H) and tumor cells (murine tumor cells (Meth A and M5076), and human tumor cells (HCT116, A549, PC-12, T98G, and HL-60)). Preliminary studies indicated that human liver cathepsin B produced Glycyl DX-8951 (G-DX-8951) from DE-310 more preferentially than DX-8951, whereas human liver cathepsin L produced DX-8951 preferentially. Release of drugs from DE-310 and cathepsin activities were measured in tumor cell types. The release of both DX-8951 and G-DX-8951 from DE-310 correlated well with cathepsin B activity of tumor cells. The release of DX-8951 was weakly, but not significantly, correlated with cathepsin L activity. In M5076 (high cathepsin activity) or Meth A (low cathepsin activity) xenograft models, the levels of DX-8951 and G-DX-8951 in M5076 were higher than in Meth A after single intravenous administration of DE-310. Our findings suggest that cathepsin B is primarily responsible for drug release from DE-310 in tumor.Keywords
This publication has 26 references indexed in Scilit:
- Quantitative acid hydrolysis of DE-310, a macromolecular carrier system for the camptothecin analog DX-8951fJournal of Pharmaceutical and Biomedical Analysis, 2007
- Paclitaxel poliglumex (XYOTAX™, CT-2103): A macromolecular taxaneJournal of Controlled Release, 2005
- DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumorsInvestigational New Drugs, 2005
- Expression of Cathepsin B and L antigen and activity is associated with early colorectal cancer progressionEuropean Journal Of Cancer, 2004
- Structure–activity relationships of carboxymethylpullulan-peptide-doxorubicin conjugates—systematic modification of peptide spacersBioorganic & Medicinal Chemistry Letters, 2000
- Antitumour activity of DX-8951f: a new camptothecin derivativeExpert Opinion on Investigational Drugs, 1998
- The crucial role of spacer groups in macromolecular prodrug designAdvanced Drug Delivery Reviews, 1996
- Liposomal formulations of cytotoxic drugsSupportive Care in Cancer, 1996
- Synthesis of Carboxymethylpullulan-Peptide-Doxorubicin Conjugates and Their Properties.CHEMICAL & PHARMACEUTICAL BULLETIN, 1995
- Pinocytic uptake and intracellular degradation of N-(2-hydroxypropyl)methacrylamide copolymers a potential drug delivery systemBiochimica et Biophysica Acta (BBA) - General Subjects, 1981